Bacterin Reports Findings for its OsteoSponge Bone Graft for Foot and Ankle Fusion

Belgrade, Mont.-based Bacterin International, a developer of bone graft materials and bioactive coatings for medical applications, reports results using OsteoSponge bone graft for foot and ankle arthrodeses procedures has been published in the peer-reviewed journal Orthopedics. It is the second publication for Bacterin that highlights clinical outcomes of OsteoSponge for foot and ankle fusion procedures.

The article reports a prospective analysis of 25 patients who underwent foot and ankle arthrodesis involving 45 total joints. Results indicated that 96 percent of patients showed radiographic fusion at six and 12 months (24 out of 25 patients) postoperative assessment, with a 97.4 percent overall fusion rate (44 out of 45 joints fused). Pain was assessed pre- and post-operatively via visual analog scale, with statistically significant improvements at six and 12 months relative to pre-operative pain scores. Functional outcomes were significantly improved at six and 12 months compared with preoperative assessment according to American Orthopaedic Foot and Ankle Society scores.

“Bacterin has made a commitment to patients, healthcare providers and healthcare facilities alike to provide best-in-class products supported by proven clinical outcomes,” said Gregory Juda, M.D., chief scientific officer for Bacterin. “We have spent a considerable amount of effort and resources supporting the clinical efficacy of our products through peer-reviewed publications in recent years and the results of this study further serve as testament to our role as a leader in the orthobiologic sector.”

The full article may be accessed here or in the March 2014 issue of Orthopedics.

Bacterin’s biologics products are used in a variety of applications including fusion in spine surgery, relief of back pain, promotion of bone growth in foot and ankle surgery, promotion of cranial healing following neurosurgery and subchondral repair in knee and other joint surgeries. Bacterin’s Medical Device division develops and licenses coatings for various medical device applications.